Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Rheumatoid Arthritis
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The immune system of patients with Rheumatoid Arthritis (RA) is different from that of people who do not have RA. The purpose of this study is to examine your immune cells and proteins before you start to take study medication and after you start treatment with an approved therapy for RA, abatacept ...
The immune system of patients with Rheumatoid Arthritis (RA) is different from that of people who do not have RA. The purpose of this study is to examine your immune cells and proteins before you start to take study medication and after you start treatment with an approved therapy for RA, abatacept that will be given in combination with Methotrexate and/or anti-rheumatic drugs (DMARDS) that are approved for the treatment of RA. This study will assess whether you have clinically responded to these medications. This assessment will also include a study of whether characteristics of your immune system were changed by therapy with the study drug, abatacept.
Tracking Information
- NCT #
- NCT03652961
- Collaborators
- Dartmouth-Hitchcock Medical Center
- Investigators
- Principal Investigator: Gregg Silverman, MD NYU Langone Health Principal Investigator: William Rigby, MD Dartmouth-Hitchcock Medical Center
Get Well Soon